Disease · MONDO_0005082
Comparisons in its trials26
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 26
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Neoadjuvant TAS 2 Months Before and During RT vs Radiation Therapy Alone: serious adverse events | 33 of 1,003 | 16 of 1,003 | 2,006 | NCT00002597 | Trial comparisons |
| TAS x 8 Weeks vs TAS x 28 Weeks: serious adverse events | 121 of 747 | 109 of 735 | 1,482 | NCT00005044 | Trial comparisons |
| Arm I: Bicalutamide + Goserelin vs Arm II: Mitoxantrone + Prednisone + Bivalutamid + Goserelin: deaths from any cause | 85 of 469 | 91 of 460 | 929 | NCT00004124 | Trial comparisons |
| Arm I: Bicalutamide + Goserelin vs Arm II: Mitoxantrone + Prednisone + Bivalutamid + Goserelin: serious adverse events | 3 of 469 | 11 of 460 | 929 | NCT00004124 | Trial comparisons |
| Treatment Group: Sipuleucel-T vs Control Arm: Active Surveillance: Efficacy of Sipuleucel-T Measured as the Percentage of Subjects Without Histological Reclassification (Gleason Group Upgrade). | 108 of 356 | 48 of 176 | 532 | NCT03686683 | Trial comparisons |
| Treatment Group: Sipuleucel-T vs Control Arm: Active Surveillance: deaths from any cause | 10 of 356 | 5 of 176 | 532 | NCT03686683 | Trial comparisons |
| Treatment Group: Sipuleucel-T vs Control Arm: Active Surveillance: serious adverse events | 74 of 345 | 22 of 176 | 521 | NCT03686683 | Trial comparisons |
| Sipuleucel-T vs APC-Placebo: serious adverse events | 82 of 338 | 40 of 168 | 506 | NCT00065442 | Trial comparisons |
| Abemaciclib vs Placebo: deaths from any cause | 81 of 206 | 72 of 187 | 393 | NCT03706365 | Trial comparisons |
| Abemaciclib vs Placebo: serious adverse events | 89 of 206 | 66 of 185 | 391 | NCT03706365 | Trial comparisons |
| Leuprolide Acetate - Formulation A vs Leuprolide Acetate - Formulation B: serious adverse events | 31 of 151 | 41 of 159 | 310 | NCT00626431 | Trial comparisons |
| PDR001+LAG525 On-treatment Period vs PDR001+LAG525 Extended Safety Follow-up Period: deaths from any cause | 9 of 76 | 18 of 76 | 152 | NCT03365791 | Trial comparisons |
| PDR001+LAG525 On-treatment Period vs PDR001+LAG525 Extended Safety Follow-up Period: serious adverse events | 31 of 76 | 4 of 76 | 152 | NCT03365791 | Trial comparisons |
| Arm I vs Arm II: serious adverse events | 20 of 29 | 9 of 28 | 57 | NCT00527124 | Trial comparisons |
| Arm A - Enzalutamide for 3 Months vs Arm B - Enzalutamide for 3 Months + PSA-TRICOM: deaths from any cause | 0 of 19 | 0 of 19 | 38 | NCT01875250 | Trial comparisons |
Arm A - Enzalutamide for 3 Months vs Arm B - Enzalutamide for 3 Months + PSA-TRICOM: Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | 19 of 19 | 19 of 19 | 38 | NCT01875250 | Trial comparisons |
| Arm A - Enzalutamide for 3 Months vs Arm B - Enzalutamide for 3 Months + PSA-TRICOM: serious adverse events | 0 of 19 | 1 of 19 | 38 | NCT01875250 | Trial comparisons |
| Arm I vs Arm II: Safety and Tolerability Assessed Using NCI CTCAE Version 4.0 | 0 of 5 | 0 of 5 | 10 | NCT01200810 | Trial comparisons |
| Arm II - RO4929097 vs Arm I - Placebo: serious adverse events | 0 of 5 | 0 of 5 | 10 | NCT01200810 | Trial comparisons |
| Group A- GDC-0449 and Androgen Ablation (LHRHa) vs Group B- Androgren Ablation (LHRHa) Alone: deaths from any cause | 0 of 4 | 0 of 5 | 9 | NCT01163084 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005082/comparisons